Here are the three trends boosting the global spinal biologics market.
1. Escalating strategic alliances. The spinal biologics field will see a lot of merger and acquisition activity, with the goal of increasing products and expanding globally. The report highlights ChoiceSpine acquiring Exactech’s spinal assets.
2. Increasing number of lumbar fusion cases. An increasing geriatric population coupled with a growing number of accidents will boost the number of lumbar spinal fusion cases.
3. Rising adoption of minimally invasive surgery. With the growing popularity of MIS, many vendors are introducing innovative technology. Patients are demanding treatments that offer quicker recoveries.
More articles on biologics:
GE Healthcare assists CBMG accelerate cell therapy manufacturing: 5 insights
Major breakthroughs in spinal biologics, disc regeneration on the horizon: 3 key thoughts from Dr. William Watters
Mayo Clinic receives FDA approval for stem cell reproduction system: 5 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
